AmerisourceBergen
Customer Huddle #15

September 23, 2020

During the call, please submit questions via the Skype window.

Both audio and visuals are available through the Skype Meeting Broadcast link and are accessible via any browser, either PC or mobile.
Today’s Speakers

Summer Richoux
Vice President,
Specialty Sales

Keyvan Nekouei
Sr. Director, Account Experience & Clinical Services

During the call, please submit questions via the Skype Q&A window.

Both audio and visuals are available through the Skype Meeting Broadcast link and are accessible via any browser, either PC or mobile.
Remdesivir Allocation Process

- **How is allocation determined?** Allocations are determined at the state level by HHS/ASPR, then at the hospital/site level by each state Department of Health. State level allocation of remdesivir is based on U.S. hospitals reporting data on suspected or confirmed COVID-19 cases every week via the HHS TeleTracking portal. This reporting process was established when ASPR began allocating donated remdesivir supply in early May 2020 and is likely already being performed by select hospital personnel.

- **How will I be contacted if my site is designated by HHS and DOH to purchase remdesivir?** If a site is designated to receive remdesivir, a member of AmerisourceBergen’s team will directly reach out to the site (email or phone).

- **How quickly must the pharmacy decide if they’ll accept their full allocation?** Within one business day. Due to the quick turn around we must receive a response quickly to fulfill allocations prior to following week allocation.

- **Which AHFS therapeutic class does remdesivir fall under?** At this time, we are unaware of an AHFS clinical designation, as this product is not an FDA-approved therapy at this time.
Continued: Remdesivir Allocation Process

- If a system wants more info on what their eligible sites purchased, how can they get that information? Provide a full list of account numbers for sites to remdesivir@amerisourcebergen.com. Any site using ABC Order can pull a purchase report from ABC Order directly.

- What if a site declines all or part of their allocation? Due to weekly cadence state DOH will not be notified of denials. However, HHS will be notified of the denied quantities per state and will incorporate the data in the following allocations for the states.

- If I have a COVID patient in critical need but have not received remdesivir, what should I do? Continue using the HHS TeleTracking system & reach out to your State Department of Health.

- If I purchase remdesivir but don’t need my full allocation, is the product returnable? Product is not returnable.

- How do selected sites order remdesivir? AmerisourceBergen will place the order on your behalf once you’ve indicated that you plan to purchase the allocation directed by HHS & DOH. If you prefer to institute a blanket approval, please let your AmerisourceBergen representative know or mail Remdesivir@amerisourcebergen.com to advise.
Specialty Product Availability & New Launches

- **RYONCIL™ from Mesoblast** will be reviewed by the FDA on September 30 under the Prescription Drug User Free Act (PDUFA)
  - Ryoncil is a stem cell therapy and is used for the treatment of acute graft versus host disease, a potentially life-threatening complication of an allogenic bone marrow transplant
  - We will provide more updates post-September 30 based on the ruling from the FDA
- **Varithena™** will no longer be available through Specialty Distribution after September 30
  - Effective October 5, 2020, Varithena, a varicose vein treatment manufactured by Boston Scientific, will be available only as a direct order from Biocompatibles.
  - **The last day for customers to place orders of Varithena through AmerisourceBergen will be Wednesday, September 30**, as Boston Scientific is not accepting orders between October 2 and October 5 to accommodate a systems change.
- **VYXEOS® from Jazz Pharmaceuticals** – Reminder that AmerisourceBergen has recently gained access to this drug. Reach out to your AmerisourceBergen representative if you have any questions on how to order or access the drug
COVID-19 Treatment Updates

- We have been getting questions about Olumiant, which is a drug that is approved by the FDA for the treatment of rheumatoid arthritis.
  - At this time, Olumiant has not received a COVID indication or authorization from the FDA for the treatment of COVID-19.
- Remdesivir is the only drug approved by the FDA for the treatment of COVID-19.
- As always, we remain committed to updating you with the latest information, and will continue to keep you informed of any potential COVID-19 treatment option.
BD Veritor™ Plus System COVID-19 Test Kits

- AmerisourceBergen will soon have BD Veritor™ Plus System Test available for purchase.
- We estimate that we will begin to have test materials in stock starting mid-October 2020. Exact date to come.
- The net price for tests (sold in kits of 30 tests per kit) is $948.75 and could be subject to rebates/discounts per customer contract.
- The actual reader must be purchased separately from BD and it will be drop-shipped.
  - If you are already using a BD reader, you will need to order a free update for that reader through BD to perform COVID tests.
- A CLIA Certificate of Waiver will be required to offer COVID-19 testing in a healthcare setting.
- Your AmerisourceBergen representative should have reached out to gauge your interest in ordering, if they have not, please reach out to them directly for information about how to purchase test kits.
Customer Service Extended Wait Times

- We are taking the following steps to mitigate the wait times, including:
  - Customer Service Specialists continue to work overtime to commit as many resources as possible
  - Continued open lines of communication with our operational teams
  - Released a technology enhancement this past weekend that we believe will drive an improvement over the next couple of days
  - Temporary support has been added to help with the extended wait times
Q & A

Please submit questions directly in the Skype window